Hisamitsu Pharmaceutical

OverviewSuggest Edit

Hisamitsu Pharmaceutical (久光製藥株式會社) is a company manufacturing external analgesic and anti-inflammatory preparations, such as medicated plasters, gels, sprays, etc. It develops transdermal anti-inflammatory analgesic drugs, including patches SALONPAS designed to treat pain and stiffness.

TypePublic
Founded1847
HQTosu, JP
Websiteglobal.hisamitsu
Employee Ratings3.5

Latest Updates

Employees (est.) (Feb 2020)2,745(-1%)
Revenue (FY, 2020)¥141 B(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Hisamitsu Pharmaceutical

NAKATOMI Kazuhide

NAKATOMI Kazuhide

President & CEO
Jim Lepis

Jim Lepis

Director of Marketing for Hisamitsu America
John Incledon

John Incledon

President and CEO at Hisamitsu America
Show more

Hisamitsu Pharmaceutical Office Locations

Hisamitsu Pharmaceutical has offices in Tosu, Chiyoda City, Fukuoka, Kanazawa and in 17 other locations
Suzhou, CN
Park Huxi, Wuzhong District
Chiyoda City, JP
2-chōme-4-1 Marunouchi
Fukuoka, JP
2-chōme-2-10 Higashinaka, Hakata-ku
Kanazawa, JP
4-chōme-106 Kuratsuki
Kyoto, JP
Kurumayacho-dori, Nakagyō-ku
Nagoya, JP
2-chōme-7-11 Nakata, Chikusa-ku
Show all (27)

Hisamitsu Pharmaceutical Financials and Metrics

Hisamitsu Pharmaceutical Revenue

Embed Graph
View revenue for all periods
Hisamitsu Pharmaceutical's revenue was reported to be ¥140.99 b in FY, 2020 which is a 1.7% decrease from the previous period.
JPY

Revenue (Q1, 2021)

24.9b

Gross profit (Q1, 2021)

15.2b

Gross profit margin (Q1, 2021), %

61.1%

Net income (Q1, 2021)

84.0m

EBIT (Q1, 2021)

1.1b

Cash (31-May-2020)

101.2b
Annual
JPYFY, 2018FY, 2019FY, 2020

Revenue

147.9b143.4b141.0b

Revenue growth, %

1%(3%)(2%)

Cost of goods sold

55.7b54.7b53.4b

Gross profit

92.2b88.7b87.6b
Quarterly
JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

36.1b37.4b36.7b33.5b35.9b33.2b29.2b34.2b35.7b24.9b

Cost of goods sold

14.0b13.6b12.7b136.0b12.5b12.0b10.9b12.0b11.7b9.7b

Gross profit

22.1b23.8b24.0b19.9b23.4b21.1b18.3b22.2b24.0b15.2b

Gross profit Margin, %

61%64%65%59%65%64%63%65%67%61%
Annual
JPYFY, 2018FY, 2019FY, 2020

Cash

117.2b110.3b107.1b

Accounts Receivable

35.2b40.0b49.2b

Inventories

17.0b15.8b15.5b

Current Assets

186.2b191.4b209.3b
JPYFY, 2018FY, 2019FY, 2020

Depreciation and Amortization

6.0b5.7b4.3b

Inventories

485.0m1.3b232.0m

Accounts Payable

(316.0m)649.0m4.9b

Cash From Operating Activities

30.5b15.8b27.4b
JPYQ1, 2018

Financial Leverage

1.2 x
Show all financial metrics

Hisamitsu Pharmaceutical Acquisitions / Subsidiaries

Company NameDateDeal Size
CRCC Media Co., Ltd.
Hisamitsu Agency Co., Ltd.
Hisamitsu America, Inc.
Hisamitsu Farmaceutica do Brasil Ltda.
Hisamitsu Italia S.r.l.
Hisamitsu Pharmaceutical (China) Co., Ltd.
Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd
Hisamitsu Pharmaceutical Technology Consulting (Beijing) Co., Ltd.
Hisamitsu UK Ltd.
Hisamitsu U.S., Inc.
Show more

Hisamitsu Pharmaceutical Revenue Breakdown

Embed Graph

Hisamitsu Pharmaceutical revenue breakdown by business segment: 97.6% from Pharmaceuticals and 2.4% from Other

Hisamitsu Pharmaceutical revenue breakdown by geographic segment: 12.1% from Other , 18.7% from USA and 69.3% from Japan

Human Capital Metrics

Embed Graph
Show all human capital metrics

Hisamitsu Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Hisamitsu Pharmaceutical Online and Social Media Presence

Embed Graph

Hisamitsu Pharmaceutical News and Updates

Notice Regarding Resignation of Board of Director and Post After Resignation

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: NAKATOMI, Kazuhide, hereinafter referred to as “Hisamitsu Pharmaceutical”) announces the resignation of the following board of director on July 28, 2020.

Notification of approval for manufacturing and marketing approval of OABLOK® PATCH in Thailand (Transdermal, Overactive bladder treatment patch)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) announces that it has obtained approval of manufacturing and marketing for OABLOK® PATCH (Generic name: oxybutynin hydro…

Notification of Voluntary Recall for Topical Analgesic Patch “SALONPAS HOT®” (Category 3 OTC Drug in Japan)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) is voluntarily recalling the following manufacturing lots of “SALONPA HOT®” (Category 3 OTC Drug in Japan) (Large) becau…

Notification of approval for manufacturing and marketing approval of the additional indications of cancer pain relief for opioid analgesic naïve patients of Fentos®Tape (Transdermal, pain management patch, Development code: HFT-290) in Japan

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) announces that it has obtained approval of the additional indications of cancer pain relief for opioid analgesic naïve p…

Salonpas Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Fourth Consecutive Year

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President: NAKATOMI Kazuhide; hereinafter “Hisamitsu Pharmaceutical”) announced that Euromonitor International Ltd. (hereinafter “Euromonitor International”), a leading international market research company, recognized “Salonpas®” as the…

Hisamitsu Pharmaceutical Frequently Asked Questions

  • When was Hisamitsu Pharmaceutical founded?

    Hisamitsu Pharmaceutical was founded in 1847.

  • Who are Hisamitsu Pharmaceutical key executives?

    Hisamitsu Pharmaceutical's key executives are NAKATOMI Kazuhide, Jim Lepis and John Incledon.

  • How many employees does Hisamitsu Pharmaceutical have?

    Hisamitsu Pharmaceutical has 2,745 employees.

  • What is Hisamitsu Pharmaceutical revenue?

    Latest Hisamitsu Pharmaceutical annual revenue is ¥141 b.

  • What is Hisamitsu Pharmaceutical revenue per employee?

    Latest Hisamitsu Pharmaceutical revenue per employee is ¥51.4 m.

  • Who are Hisamitsu Pharmaceutical competitors?

    Competitors of Hisamitsu Pharmaceutical include Luye Pharma, Livzon Pharmaceutical Group and Jiangsu Hansoh Pharmaceutical Group.

  • Where are Hisamitsu Pharmaceutical offices?

    Hisamitsu Pharmaceutical has offices in Tosu, Chiyoda City, Fukuoka, Kanazawa and in 17 other locations.

  • How many offices does Hisamitsu Pharmaceutical have?

    Hisamitsu Pharmaceutical has 27 offices.